.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,629,179

« Back to Dashboard

Claims for Patent: 8,629,179

Title:Methods and devices for providing prolonged drug therapy
Abstract: Methods and devices for maintaining a desired therapeutic drug effect over a prolonged therapy period are provided. In particular, oral dosage forms that release drug within the gastrointestinal tract at an ascending release rate over an extended time period are provided. The dosage forms may additionally comprise an immediate-release dose of drug.
Inventor(s): Gupta; Suneel K. (Sunnyvale, CA), Guinta; Diane R. (Palo Alto, CA), Christopher; Carol A. (Belmont, CA), Saks; Samuel R. (Burlingame, CA), Hamel; Lawrence G. (Mountain View, CA)
Assignee: Alza Corporation (Palo Alto, CA)
Application Number:12/581,699
Patent Claims: 1. A tablet oral dosage form for effectively treating Attention Deficit Disorder or Attention Deficit Hyperactivity Disorder in a subject comprising: an immediate release portion comprising methylphenidate or a pharmaceutically effective salt thereof; and a sustained release portion comprising methylphenidate or a pharmaceutically effective salt thereof and a pharmaceutically acceptable carrier, wherein: said dosage form releases said methylphenidate over a period comprising first, second, third, fourth, fifth, and sixth sequential one-hour time intervals, and said sustained release portion releases more of said methylphenidate during said second interval than during said first interval, more of said methylphenidate during said third interval than during said second interval, and more of said methylphenidate during said fourth interval than during said third interval.

2. The dosage form according to claim 1 wherein said dosage form releases said methylphenidate over a period comprising first, second, third, fourth, fifth, sixth, seventh, and eighth sequential one-hour time intervals, and said sustained release portion releases more of said methylphenidate during said eighth interval than during said seventh interval.

3. The dosage form according to claim 1 wherein said sustained release portion releases more of said methylphenidate during said fifth interval than during said fourth interval.

4. The dosage form according to claim 1 wherein said sustained release portion releases more of said methylphenidate during said sixth interval than during said fifth interval.

5. The dosage form according to claim 4 wherein said sustained release portion releases less of said methylphenidate during a seventh one-hour time interval than during said sixth interval.

6. The dosage form according to claim 1 wherein said dosage form provides a substantially ascending blood plasma concentration of said methylphenidate or pharmaceutically effective salt thereof from 2.5 hours following administration to 5.5 hours following administration.

7. The dosage form according to claim 1 wherein said dosage form provides a substantially ascending blood plasma concentration of said methylphenidate or pharmaceutically effective salt thereof from 1.5 to 5.5 hours following administration.

8. The dosage form according to claim 1 wherein said dosage form provides a substantially ascending blood plasma concentration of said methylphenidate or pharmaceutically effective salt thereof up to about 5.5 hours following administration.

9. The dosage form according to claim 1 wherein said dosage form provides a substantially ascending blood plasma concentration of said methylphenidate or pharmaceutically effective salt thereof up to about 6.5 hours following administration.

10. The dosage form according to claim 1 wherein said dosage form provides a substantially ascending blood plasma concentration of said methylphenidate or pharmaceutically effective salt thereof up to about 8 hours following administration.

11. The dosage form according to claim 1 wherein said dosage form provides a substantially ascending blood plasma concentration of said methylphenidate or pharmaceutically effective salt thereof from 2.5 hours following administration to 6.5 hours following administration.

12. The dosage form according to claim 1 wherein said dosage form provides a substantially ascending blood plasma concentration of said methylphenidate or pharmaceutically effective salt thereof from 2.5 hours following administration to 8 hours following administration.

13. The dosage form according to claim 1 wherein said dosage form provides a substantially ascending blood plasma concentration of said methylphenidate or pharmaceutically effective salt thereof from 1.5 hours following administration to 8 hours following administration.

14. The dosage form according to claim 1 wherein said dosage form provides a blood plasma concentration of said methylphenidate or pharmaceutically effective salt thereof that is greater at about 8 hours following administration than at 2.5 hours following administration.

15. The dosage form according to claim 1 wherein said sustained release portion comprises methylphenidate hydrochloride.

16. The dosage form according to claim 1 wherein said dosage form is non-osmotic.

17. The dosage form according to claim 1 wherein said dosage form is osmotic.

18. The dosage form according to claim 1 wherein the methylphenidate hydrochloride in said immediate release coating is released primarily during said first interval.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc